BARTESAGHI, RENATA
 Distribuzione geografica
Continente #
NA - Nord America 4.967
AS - Asia 3.266
EU - Europa 3.084
AF - Africa 388
SA - Sud America 191
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 11.902
Nazione #
US - Stati Uniti d'America 4.928
SG - Singapore 1.165
CN - Cina 962
IT - Italia 784
GB - Regno Unito 677
VN - Vietnam 501
DE - Germania 443
SE - Svezia 305
HK - Hong Kong 270
IN - India 155
BR - Brasile 135
TG - Togo 129
RU - Federazione Russa 126
UA - Ucraina 124
NL - Olanda 123
FR - Francia 115
IE - Irlanda 108
CI - Costa d'Avorio 94
CH - Svizzera 63
SC - Seychelles 63
ZA - Sudafrica 60
KR - Corea 56
JO - Giordania 45
BG - Bulgaria 43
EE - Estonia 43
JP - Giappone 41
FI - Finlandia 37
BE - Belgio 31
AR - Argentina 29
NG - Nigeria 29
CA - Canada 25
IR - Iran 17
AT - Austria 15
MX - Messico 13
EC - Ecuador 12
PL - Polonia 12
ID - Indonesia 10
GR - Grecia 9
TR - Turchia 9
BD - Bangladesh 7
AE - Emirati Arabi Uniti 5
CL - Cile 5
LT - Lituania 5
MY - Malesia 5
AU - Australia 4
CO - Colombia 4
ES - Italia 4
LB - Libano 4
PH - Filippine 4
PY - Paraguay 4
RO - Romania 4
MA - Marocco 3
A2 - ???statistics.table.value.countryCode.A2??? 2
HR - Croazia 2
HU - Ungheria 2
IQ - Iraq 2
KE - Kenya 2
SA - Arabia Saudita 2
TN - Tunisia 2
AL - Albania 1
AO - Angola 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CM - Camerun 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DZ - Algeria 1
ET - Etiopia 1
IL - Israele 1
JM - Giamaica 1
MD - Moldavia 1
MZ - Mozambico 1
NO - Norvegia 1
PK - Pakistan 1
PT - Portogallo 1
RE - Reunion 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
UY - Uruguay 1
VE - Venezuela 1
Totale 11.902
Città #
Singapore 813
Southend 581
Fairfield 565
Chandler 512
Ashburn 472
Santa Clara 331
Bologna 290
Houston 275
Hong Kong 267
Woodbridge 266
Wilmington 262
Seattle 251
Ann Arbor 211
Cambridge 201
Hefei 188
Dong Ket 153
Princeton 147
Beijing 143
Lomé 129
Dublin 108
Boardman 102
Abidjan 94
Ho Chi Minh City 89
Hanoi 84
Jacksonville 78
Nanjing 59
Westminster 59
Frankfurt am Main 58
Bern 56
Seoul 56
Los Angeles 53
Padova 53
Falls Church 52
Turin 51
Amman 45
Berlin 43
Sofia 43
Buffalo 42
Milan 37
Redmond 36
San Diego 36
Tokyo 35
Shenyang 34
Dallas 30
Brussels 28
Munich 28
Abeokuta 27
Helsinki 26
Saint Petersburg 26
New York 25
Jinan 24
Rimini 22
Hebei 21
Nanchang 21
Tianjin 21
Redondo Beach 20
Bengaluru 19
Changsha 18
São Paulo 18
Guangzhou 17
Dearborn 16
Mülheim 16
Shanghai 16
Chicago 15
Redwood City 15
Rome 15
The Dalles 14
Toronto 14
Zhengzhou 14
Taizhou 13
Amsterdam 12
Des Moines 12
Florence 12
Mahé 12
Trento 12
Bremen 11
Phoenix 11
Ardabil 10
Bristol 10
London 10
Norwalk 10
Council Bluffs 9
Falkenstein 9
Olalla 9
Udine 9
Wuhan 9
Bolzano 8
Bắc Ninh 8
Da Nang 8
Meldola 8
Naples 8
Vienna 8
Ha Long 7
Haikou 7
Hải Dương 7
Monmouth Junction 7
Portsmouth 7
Brooklyn 6
Düsseldorf 6
Hangzhou 6
Totale 8.267
Nome #
CDKL5 protein substitution therapy rescues neurological phenotypes of a mouse model of CDKL5 disorder 297
Neonatal therapy with clenbuterol and salmeterol restores spinogenesis and dendritic complexity in the dentate gyrus of the Ts65Dn model of Down syndrome 280
A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis and hippocampus-dependent memory in the Ts65Dn mouse model of DS 260
Impaired brain mitochondrial bioenergetics in the ts65dn mouse model of down syndrome is restored by neonatal treatment with the polyphenol 7,8-dihydroxyflavone 211
Obstructive sleep apneas naturally occur in mice during REM sleep and are highly prevalent in a mouse model of Down syndrome 204
HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder 203
Treatment with the flavonoid 7,8-Dihydroxyflavone: a promising strategy for a constellation of body and brain disorders 199
Age-related impairment of olfactory bulb neurogenesis in the Ts65Dn mouse model of Down syndrome 197
Abnormal development of the inferior temporal region in fetuses with Down Syndrome 194
CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells 192
Timing of Treatment with the Flavonoid 7,8-DHF Critically Impacts on Its Effects on Learning and Memory in the Ts65Dn Mouse 192
Lithium Restores Age Related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome 190
Cyclic AMP-mediated regulation of transcription factor Lot1 expression in cerebellar granule cells. 189
The amyloid precursor protein (APP) triplicated gene impairs neuronal precursor differentiation and neurite development through two different domains in the Ts65Dn mouse model for down syndrome. 189
Postnatal neurogenesis in the dentate gyrus of the guinea pig 187
Inhibition of GSK3β rescues hippocampal development and learning in a mouse model of CDKL5 disorder 187
APP-dependent alteration of GSK3β activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome. 184
Neurochemical correlates of nicotine neurotoxicity on rat habenulo-interpeduncular cholinergic neurons. 182
Early Pharmacotherapy with Fluoxetine Rescues Dendritic Pathology in the Ts65Dn Mouse Model of Down Syndrome 182
Epigallocatechin gallate: A useful therapy for cognitive disability in Down syndrome? 181
APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome. 176
Widespread impairment of cell proliferation in the neonate Ts65Dn mouse, a model for Down syndrome. 173
Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice 172
Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome 170
Sex differences in the stereological parameters of the hippocampal dentate gyrus of the guinea pig before puberty 169
Choline acetyltransferase activity at different ages in brain of Ts65Dn mice, an animal model for Down's syndrome and related neurodegenerative diseases. 169
Early appearance of developmental alterations in the dendritic tree of the hippocampal granule cells in the Ts65Dn model of Down syndrome 169
Cell cycle elongation impairs proliferation of cerebellar granule cell precursors in the Ts65Dn Mouse, an animal model for Down syndrome. 167
Topographic activation of the medial entorhinal cortex by presubicular commissural projections. 165
Early Pharmacotherapy Restores Neurogenesis and Cognitive Performance in the Ts65Dn Mouse Model for Down Syndrome 165
Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome 163
SNX27, a protein involved in down syndrome, regulates GPR17 trafficking and oligodendrocyte differentiation 159
Parallel activation of field CA2 and dentate gyrus by synaptically elicited perforant path volleys. 157
Neonatal treatment with cyclosporine A restores neurogenesis and spinogenesis in the Ts65Dn model of Down syndrome 154
Early appearance of dendritic alterations in neocortical pyramidal neurons of the Ts65Dn model of Down syndrome 154
Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3β signaling. 153
Neuroanatomical alterations and synaptic plasticity impairment in the perirhinal cortex of the Ts65Dn mouse model of Down syndrome 152
Subicular hypotrophy in fetuses with Down syndrome and in the Ts65Dn model of Down syndrome. 152
Nitric oxide negatively regulates proliferation and promotes neuronal differentiation through N-Myc downregulation. 151
Impact of environmental enrichment on neurogenesis in the dentate gyrus during the early postnatal period. 151
Proliferation of cerebellar precursor cells is negatively regulated by nitric oxide in newborn rat. 150
Effect of early isolation on signal transfer in the entorhinal cortex-dentate-hippocampal system 149
Neuroanatomical Alterations in Higher-Order Thalamic Nuclei of Fetuses With Down Syndrome 149
CB1 cannabinoid receptors increase neuronal precursor proliferation through AKT/GSK-3{beta}/{beta}-catenin signaling 147
Early-occurring proliferation defects in peripheral tissues of the Ts65Dn mouse model of Down syndrome are associated with patched1 over expression 145
The flavonoid 7,8-DHF fosters prenatal brain proliferation potency in a mouse model of Down syndrome 145
Sex differences in the hilar mossy cells of the guinea-pig before puberty. 144
Pharmacotherapy with Fluoxetine Restores Functional Connectivity from the Dentate Gyrus to Field CA3 in the Ts65Dn Mouse Model of Down Syndrome 142
Increased hippocampal epigenetic age in the Ts65Dn mouse model of Down Syndrome 140
Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with Down syndrome. 138
Timing of therapies for downsyndrome: The sooner, the better 138
Lot1 is a key element of the pituitary adenylate cyclase-activating polypeptide (PACAP)/cyclic AMP pathway that negatively regulates neuronal precursor proliferation. 137
Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood 137
Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model. 131
null 130
Is it possible to improve neurodevelopmental abnormalities in Down syndrome? 129
Treatment with corn oil improves neurogenesis and cognitive performance in the Ts65Dn mouse model of Down syndrome. 129
Postnatal neurogenesis in the hippocampal dentate gyrus and subventricular zone of the Goettingen minipig. 125
Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome 119
Neonatal isolation impairs neurogenesis in the dentate gyrus of the guinea pig. 118
Reversal of neurodevelopmental impairment and cognitive enhancement by pharmacological intervention with the polyphenol polydatin in a Down syndrome model 117
Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome 111
Targeting APP/AICD in Down syndrome 110
The Challenging Pathway of Treatment for Neurogenesis Impairment in Down Syndrome: Achievements and Perspectives 108
Effects of early environment on field CA2 pyramidal neurons in the guinea-pig 108
Effect of early isolation on the synaptic function in the dentate gyrus and field CA1 of the guinea pig. 107
Input-output relations in the entorhinal cortex-dentate-hippocampal system: evidence for a non-linear transfer of signals. 107
Cellularity Defects Are Not Ubiquitous in the Brains of Fetuses With Down Syndrome 103
null 100
Dendritic phenotype and proliferation potency in the hippocampal dentate gyrus of the Ts66Yah model of Down syndrome 97
null 97
New perspectives for the rescue of cognitive disability in down syndrome 96
Epigallocatechin-3-gallate: Linking the neurogenesis, hippocampus, and Down syndrome 93
Lithium restores neurogenesis in the subventricular zone of the Ts65Dn mouse, a model for Down sindrome 91
Neurogenesis impairment: An early developmental defect in Down syndrome 88
null 83
Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice. 79
Sex differences in the hippocampal dentate gyrus of the guinea-pig before puberty 64
Advocating for increased awareness and research on Down syndrome 58
Effects of early environment on pyramidal neuron morphology in field CA1 of the guinea-pig 38
Sex differences in the hilar mossy cells of the guinea-pig before puberty 36
Nitric oxide regulates cGMP-dependent cAMP-responsive element binding protein phosphorylation and Bcl-2 expression in cerebellar neurons: Implication for a survival role of nitric oxide 29
Effects of early isolation on layer II neurons in the entorhinal cortex of the guinea pig 25
“Administration of the BDNF mimetic 7,8-Dihydroxyflavone during adolescence rescues neuron maturation and improves hippocampus- dependent memory in the Ts65Dn mouse model of Down syndrome”. 23
“Il trattamento adolescenziale con il BDNF mimetico 7,8-diidrossiflavone influenza la metilazione del DNA nell'ippocampo del modello Ts65Dn di sindrome di Down” 17
“Early pharmacotherapies for the rescue of intellectual disability in Down syndrome” 15
“Adolescence represents an important window of opportunity for the rescue of dendritic pathology with a BDNF mimetic in a mouse model of Down syndrome” 14
“Analisi dell’espressione genica in ippocampi di topi Ts65Dn sottoposti a trattamento adolescenziale con il BDNF-mimetico 7,8 diidrossiflavone” 13
“Il trattamento con il polifenolo Polidatina migliora lo sviluppo cerebrale e la memoria ippocampo-dipendente nel topo Ts65Dn, modello di sindrome di Down” 12
“Effects of 7,8-dihydroxyflavone treatment on DNA methylation profiles of adolescent Ts65Dn mice hippocampus” 11
“Trattamento adolescenziale con il BDNF mimetico 7,8- diidrossiflavone: una strategia utile per migliorare lo sviluppo della fascia dentata ippocampica nel modello Ts65Dn di sindrome di Down”. 11
Totale 12.144
Categoria #
all - tutte 34.218
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.218


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021747 0 0 0 0 0 78 17 78 98 90 56 330
2021/20221.366 82 55 92 84 145 94 81 80 57 93 250 253
2022/20231.896 171 364 108 253 111 151 56 84 283 29 137 149
2023/2024489 29 83 29 50 38 100 14 22 8 36 49 31
2024/20252.091 118 214 143 168 421 120 149 87 40 159 100 372
2025/20262.397 394 401 374 384 573 271 0 0 0 0 0 0
Totale 12.144